Analgosedative adjuncT keTAmine Infusion iN Mechanically vENTilated ICU Patients

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 17% of the time (276 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-05-06. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientsbraininjurystatusstage
  Phrases that lowered it: investigatedoseadultketamineand safety
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Sponsor's past termination rate: 8.8% (raises risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 15.8% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 2 (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 93.3% (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 14 (raises risk) · Who can join
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Drug's FAERS reports before start: 4684 (raises risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Collaborators: 0 (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients NCT05803551 · started 2025 · scored riskier than 98% of active trials terminated
• Ketamine Efficacy for Acute Severe Bronchospasm in ICU: MACANUDO Trial NCT03000413 · started 2015 · scored riskier than 34% of active trials completed
• Ketamine / Propofol Admixture Ketofol at Induction in the Critically Ill Against Etomidate: KEEP PACE Trial NCT02105415 · started 2014 · scored riskier than 93% of active trials completed
• Ketamine Low dOse Evaluation on Morphine Consumption in Traumatic Patient NCT04833816 · started 2022 · scored riskier than 92% of active trials completed
• Immunomodulatory Properties of Ketamine in Sepsis NCT01089361 · started 2009 · scored riskier than 83% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.